DK3265115T3 - Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud - Google Patents
Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud Download PDFInfo
- Publication number
- DK3265115T3 DK3265115T3 DK16759540.4T DK16759540T DK3265115T3 DK 3265115 T3 DK3265115 T3 DK 3265115T3 DK 16759540 T DK16759540 T DK 16759540T DK 3265115 T3 DK3265115 T3 DK 3265115T3
- Authority
- DK
- Denmark
- Prior art keywords
- abaloparatide
- alendronate
- reduction
- combined
- bone fractures
- Prior art date
Links
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title 1
- 208000010392 Bone Fractures Diseases 0.000 title 1
- BVISQZFBLRSESR-XSCWXTNMSA-N abaloparatide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C1=CN=CN1 BVISQZFBLRSESR-XSCWXTNMSA-N 0.000 title 1
- 229950001959 abaloparatide Drugs 0.000 title 1
- 108010038051 abaloparatide Proteins 0.000 title 1
- 229940062527 alendronate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127729P | 2015-03-03 | 2015-03-03 | |
| US201562165841P | 2015-05-22 | 2015-05-22 | |
| US201562201564P | 2015-08-05 | 2015-08-05 | |
| US201562239733P | 2015-10-09 | 2015-10-09 | |
| US201662278762P | 2016-01-14 | 2016-01-14 | |
| PCT/US2016/020787 WO2016141250A1 (en) | 2015-03-03 | 2016-03-03 | USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3265115T3 true DK3265115T3 (da) | 2022-09-05 |
Family
ID=56849024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16759540.4T DK3265115T3 (da) | 2015-03-03 | 2016-03-03 | Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud |
Country Status (8)
| Country | Link |
|---|---|
| US (8) | US20170065682A1 (enExample) |
| EP (2) | EP4137147A3 (enExample) |
| JP (5) | JP6755256B2 (enExample) |
| AU (3) | AU2016226103A1 (enExample) |
| CA (1) | CA2977812A1 (enExample) |
| DK (1) | DK3265115T3 (enExample) |
| ES (1) | ES2927067T3 (enExample) |
| WO (1) | WO2016141250A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017253674B2 (en) | 2016-04-18 | 2021-07-29 | Kindeva Drug Delivery L.P. | Formulations of abaloparatide, transdermal patches thereof, and uses thereof |
| CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| EP3796941A4 (en) | 2018-05-30 | 2022-12-28 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| EP3908605A1 (en) * | 2019-01-11 | 2021-11-17 | Radius Health, Inc. | Methods for detecting neutralizing antibodies to parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) analog |
| WO2020166561A1 (ja) | 2019-02-14 | 2020-08-20 | 富士フイルム株式会社 | 骨折リスク評価値取得装置及びその作動方法並びに骨折リスク評価値取得プログラム |
| CN114364327A (zh) * | 2019-09-12 | 2022-04-15 | 雷迪厄斯健康公司 | 用阿巴帕肽改善脊柱融合的方法 |
| CN112646042A (zh) * | 2019-10-10 | 2021-04-13 | 陕西麦科奥特科技有限公司 | 活性多肽化合物 |
| AU2022205801A1 (en) * | 2021-01-05 | 2023-07-13 | Radius Health, Inc. | Treatment of long bone fractures with abaloparatide |
| EP4346878A1 (en) * | 2021-05-25 | 2024-04-10 | Radius Health, Inc. | Treatment and prevention of osteoporosis in high body mass index individuals |
| WO2025032376A1 (en) * | 2023-08-04 | 2025-02-13 | Precise Biopharma Pvt Ltd | A room temperature stable solution for injection of abaloparatide |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| MXPA04006728A (es) * | 2002-01-10 | 2005-08-19 | Osteotrophin Llc | Tratamiento de desordenes oseos con medicamentos anabolicos esqueleticos. |
| CA2621264A1 (en) * | 2005-09-06 | 2007-11-15 | Zelos Therapeutics, Inc. | Parathyroid hormone analogues and methods of use |
| AR062522A1 (es) * | 2006-08-25 | 2008-11-12 | Ares Trading Sa | Tratamiento de desordenes en cartilagos |
| US7803770B2 (en) * | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| JP5375611B2 (ja) * | 2006-10-03 | 2013-12-25 | ラジウス ヘルス，インコーポレイテッド | 骨同化作用を有するタンパク質のための薬物送達方法 |
| WO2010022176A1 (en) * | 2008-08-19 | 2010-02-25 | Ferring International Center S.A. | Methods of treatment for skeletal conditons |
| US20130006217A1 (en) * | 2011-04-22 | 2013-01-03 | Gary Hattersley | METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES |
| WO2014004465A1 (en) * | 2012-06-25 | 2014-01-03 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| SI3359241T1 (sl) * | 2015-10-09 | 2021-11-30 | Radius Health, Inc. | Formulacije PTHRP-analogov, transdermalni obliži le-teh in uporabe le-teh |
-
2016
- 2016-03-03 EP EP22179423.3A patent/EP4137147A3/en active Pending
- 2016-03-03 ES ES16759540T patent/ES2927067T3/es active Active
- 2016-03-03 CA CA2977812A patent/CA2977812A1/en active Pending
- 2016-03-03 DK DK16759540.4T patent/DK3265115T3/da active
- 2016-03-03 AU AU2016226103A patent/AU2016226103A1/en not_active Abandoned
- 2016-03-03 JP JP2017546245A patent/JP6755256B2/ja active Active
- 2016-03-03 EP EP16759540.4A patent/EP3265115B1/en not_active Revoked
- 2016-03-03 WO PCT/US2016/020787 patent/WO2016141250A1/en not_active Ceased
- 2016-08-31 US US15/253,545 patent/US20170065682A1/en not_active Abandoned
-
2017
- 2017-09-01 US US15/694,658 patent/US20170368148A1/en not_active Abandoned
-
2019
- 2019-09-10 US US16/566,499 patent/US20200061160A1/en not_active Abandoned
-
2020
- 2020-06-16 US US16/903,256 patent/US20200376088A1/en not_active Abandoned
- 2020-08-25 JP JP2020141522A patent/JP7049412B2/ja active Active
- 2020-11-10 AU AU2020267182A patent/AU2020267182A1/en not_active Abandoned
-
2021
- 2021-09-10 US US17/471,543 patent/US20220125887A1/en not_active Abandoned
-
2022
- 2022-03-25 JP JP2022050196A patent/JP2022075999A/ja active Pending
-
2023
- 2023-04-06 US US18/296,801 patent/US20230381283A1/en not_active Abandoned
- 2023-05-19 US US18/320,638 patent/US20230321199A1/en not_active Abandoned
- 2023-07-19 JP JP2023117588A patent/JP2023129523A/ja active Pending
-
2024
- 2024-05-03 AU AU2024202952A patent/AU2024202952A1/en active Pending
-
2025
- 2025-03-04 US US19/070,407 patent/US20250195619A1/en not_active Abandoned
- 2025-04-10 JP JP2025064970A patent/JP2025100689A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3265115A1 (en) | 2018-01-10 |
| JP2022075999A (ja) | 2022-05-18 |
| JP2018508530A (ja) | 2018-03-29 |
| CA2977812A1 (en) | 2016-09-09 |
| US20250195619A1 (en) | 2025-06-19 |
| WO2016141250A1 (en) | 2016-09-09 |
| US20200376088A1 (en) | 2020-12-03 |
| EP3265115B1 (en) | 2022-06-22 |
| US20220125887A1 (en) | 2022-04-28 |
| US20200061160A1 (en) | 2020-02-27 |
| US20230321199A1 (en) | 2023-10-12 |
| US20170368148A1 (en) | 2017-12-28 |
| EP4137147A3 (en) | 2023-04-05 |
| JP6755256B2 (ja) | 2020-09-16 |
| JP2020189884A (ja) | 2020-11-26 |
| AU2020267182A1 (en) | 2020-12-03 |
| AU2024202952A1 (en) | 2024-05-23 |
| AU2016226103A1 (en) | 2017-08-31 |
| JP2023129523A (ja) | 2023-09-14 |
| ES2927067T3 (es) | 2022-11-02 |
| US20230381283A1 (en) | 2023-11-30 |
| JP2025100689A (ja) | 2025-07-03 |
| US20170065682A1 (en) | 2017-03-09 |
| JP7049412B2 (ja) | 2022-04-06 |
| EP4137147A2 (en) | 2023-02-22 |
| EP3265115A4 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3265115T3 (da) | Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3668851T3 (da) | Fremgangsmåde til fremstilling af thiocarbonater | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3294720T3 (da) | Fremgangsmåde til fremstilling af terpinolenepoxid | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3119408T3 (da) | Overfladereageret calciumkarbonat til desensibilisering af tænder | |
| DK3303618T3 (da) | Fremgangsmåder til prognose af prostatacancer | |
| DK3386531T3 (da) | Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3390422T3 (da) | Krystalformer af lnt | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom |